Total and undercarboxylated osteocalcin predict changes in insulin sensitivity and β cell function in elderly men at high cardiovascular risk
Total and undercarboxylated osteocalcin predict changes in insulin sensitivity and β cell function in elderly men at high cardiovascular risk
复制标题
DOI：
10.3945/ajcn.111.016642
复制
发表时间：
2012-01-01
影响因子：
7.1
通讯作者：
Salas-Salvado, Jordi
中科院分区：
文献类型：
--
作者：
Bullo, Monica;Maria Moreno-Navarrete, Jose;Salas-Salvado, Jordi
背景：在实验模型中骨钙素与胰岛素分泌有关。很少有前瞻性研究评估了人类循环骨钙素浓度与胰岛素分泌和敏感性之间的关系。目的：目的是检查心血管高危老年男性的循环骨钙素形式与胰岛素分泌和敏感性之间的横断面和纵向关系。设计：我们检查了血清中总骨钙素和羧化骨钙素不足 (ucOC) 的血清测量值与空腹血糖、空腹胰岛素、HOMA-IR 和 HOMA β 细胞功能 (HOMA-BCF) 之间的横断面和纵向关系。 79名老年男性。我们还检查了骨钙素的 2 年变化与空腹血糖、胰岛素、HOMA-IR 和 HOMA-BCF 变化之间的关联。结果：在调整后的多变量线性回归分析中，血清骨钙素的增加与 HOMA-BCF 的增加显着相关（β 系数：2.87；95% CI：0.23、5.52；P = 0.033），ucOC 的变化与HOMA-IR（β系数：-0.31；95% CI：-0.60，0.03；P = 0.032）。此外，在未服用口服抗糖尿病药物的受试者中，即使在调整了 BMI、体力活动、干预组、是否存在 2 型糖尿病以及每个因变量的基线值后，基线骨钙素浓度仍与较高的空腹胰岛素浓度和 HOMA-BCF 呈正相关。 结论：血清骨钙素和 ucOC 的变化与胰岛素分泌和敏感性的改善相关，这表明骨在 2 型糖尿病的发生中可能发挥作用。该试验在 ClinicalTrials.gov 上注册为 ISRCTN35739639。美国临床营养杂志 2012；95：249-55。
Background: Osteocalcin has been related to insulin secretion in experimental models. Few prospective studies have evaluated the association between circulating osteocalcin concentrations and insulin secretion and sensitivity in humans.Objective: The objective was to examine cross-sectional and longitudinal associations between circulating forms of osteocalcin and insulin secretion and sensitivity in elderly men at high cardiovascular risk.Design: We examined cross-sectional and longitudinal associations between serum measurements of total osteocalcin and undercarboxylated osteocalcin (ucOC) with fasting glucose, fasting insulin, HOMA-IR, and HOMA beta cell function (HOMA-BCF) in 79 elderly men. We also examined the association between 2-y changes in osteocalcin and changes in fasting glucose, insulin, HOMA-IR, and HOMA-BCF.Results: In an adjusted multivariable linear regression analysis, increases in serum osteocalcin were significantly associated with an increase in HOMA-BCF (beta coefficient: 2.87; 95% CI: 0.23, 5.52; P = 0.033), and changes in ucOC were linked to a decrease in HOMA-IR (beta coefficient: -0.31; 95% CI: -0.60, 0.03; P = 0.032). Moreover, in subjects not taking oral antidiabetic drugs, baseline osteocalcin concentrations were positively associated with higher fasting insulin concentrations and HOMA-BCF even after adjustment for BMI, physical activity, intervention group, presence of type 2 diabetes mellitus, and baseline values of each dependent variable.Conclusions: Changes in serum osteocalcin and ucOC are associated with an improvement in insulin secretion and sensitivity, which suggests a possible role of bone in the development of type 2 diabetes. This trial is registered at clinicaltrials.gov as ISRCTN35739639. Am J Clin Nutr 2012;95:249-55.